Immunovant, Inc. (NASDAQ: IMVT) Chief Operating Officer Melanie Gloria reduced her stake in the company through a series of transactions totaling $678,604 on June 26, 2026, according to recent Securities and Exchange Commission filings. The execution of these sales involved the liquidation of 17,714 shares of Immunovant common stock across distinct pricing tiers.
Analysis of the transaction data reveals two primary components to the sale. The first component accounted for 14,748 shares, disposed of at a weighted average price of $38.18 per share. These specific units were traded in multiple instances with prices fluctuating between $37.77 and $38.56. A secondary transaction involved the sale of 2,966 shares at a weighted average price of $38.95 per share, with individual trade prices ranging from $38.78 to $39.13. Collectively, the sales occurred within a price band of $37.77 to $39.13 per share.
Post-transaction, Gloria's direct ownership in Immunovant stands at 224,393 shares. The insider activity occurs against a backdrop where Immunovant shares are trading at $38.77, a figure just 1% below the stock's 52-week high of $39.28. According to InvestingPro analysis, the stock is currently positioned on the "Most Overvalued" list, suggesting it trades above its calculated Fair Value. Despite this valuation metric, the stock has generated a 137% return over the past year.
While insider selling is underway, the broader market sentiment remains influenced by significant analyst upgrades and clinical developments. Stifel reaffirmed its Buy rating and maintained a $49 price target following the company's fourth-quarter results and data from the IMVT-1402 trial in rheumatoid arthritis. The trial showed response rates where over 70% of participants achieved ACR20.
Additionally, H.C. Wainwright increased its price target to $40 from $35, citing compelling response rates in a Phase 2 rheumatoid arthritis study. BofA Securities also raised its price target to $43 from $32, driven by a higher peak sales outlook for IMVT-1402, particularly in markets for Graves' disease and challenging cases of rheumatoid arthritis. The firm highlighted these areas as significant growth opportunities.
Roivant Sciences, which includes Immunovant in its portfolio, reported a strong cash position in its fourth-quarter earnings for fiscal year 2026, despite missing EPS expectations. These developments highlight ongoing interest and positive sentiment from investors regarding Immunovant's potential in advancing its clinical programs.
The stock closed at $38.77, up $0.53 or 1.37%, with after-hours trading showing a slight decline to $38.84. The convergence of insider liquidation and strong analyst optimism presents a complex picture for the pharmaceutical sector, where clinical trial success drives valuation but insider selling can signal profit-taking at peak levels.